Challenges and opportunities in developing and marketing vaccines for OIE List A and emerging animal diseases.
Veterinary pharmaceutical products generated 14.5 billion U.S. Dollars (USD) in worldwide sales in 2000, with biological products contributing 16.2 percent or 2.3 billion USD. The leading biological products were foot-and-mouth disease (FMD) vaccines, with 284 million USD in sales, representing 26.4 percent of the entire livestock biological business. Despite the potential opportunities for the biologicals industry, non-vaccination policies and undefined control and eradication strategies have deterred the private sector from significant investments in the research and development of vaccines against List A diseases. The primary research focus remains vaccines for infectious diseases that have an impact on current domestic herd health management systems. Changing the vaccine paradigm, investing in new technologies, and creating the future by integrating into key alliances with producers and regulatory authorities will be paramount in protecting our poultry and livestock industries against highly infectious diseases and potential acts of bioterrorism.
Gay
C G
CG
Pfizer Inc., Animal Health Group, New York, NY, USA. ccg@ars.usda.gov
Salt
J
J
Balaski
C
C
D000820:Animal Diseases / Q000276:immunology* / Q000517:prevention & control*; D000818:Animals; D003365:Costs and Cost Analysis; D007390:International Agencies; D014481:United States; D014611:Vaccination / Q000662:veterinary; D014612:Vaccines / Q000627:therapeutic use*; D019155:Veterinary Drugs / Q000191:economics
D014612:Vaccines; D019155:Veterinary Drugs